

1 **ProbeTools: Designing hybridization probes for targeted genomic sequencing**
2 **of diverse and hypervariable viral taxa**

3

4 Kevin S. Kuchinski ^{1*}, Jun Duan ¹, Chelsea Himsworth ^{2,3}, William Hsiao ^{1,4}, Natalie A. Prystajecky ^{1,5}

5

6 ¹ Department of Pathology and Laboratory Medicine; University of British Columbia; Vancouver, British Columbia,
7 Canada

8 ² Animal Health Centre; British Columbia Ministry of Agriculture, Food, and Fisheries; Abbotsford, British
9 Columbia, Canada

10 ³ School of Population and Public Health; University of British Columbia; Vancouver, British Columbia, Canada

11 ⁴ Faculty of Health Sciences; Simon Fraser University; Burnaby, British Columbia, Canada

12 ⁵ Public Health Laboratory; British Columbia Centre for Disease Control; Vancouver, British Columbia, Canada

13 * Corresponding author

14 **ABSTRACT**

15 **Background:** Sequencing viruses in many specimens is hindered by excessive background
16 material from hosts, microbiota, and environmental organisms. Consequently, enrichment of
17 target genomic material is necessary for practical high-throughput viral genome sequencing.
18 Hybridization probes are widely used for enrichment in many fields, but their application to viral
19 sequencing faces a major obstacle: it is difficult to design panels of probe oligo sequences that
20 broadly target many viral taxa due to their rapid evolution, extensive diversity, and genetic
21 hypervariability. To address this challenge, we created ProbeTools, a package of bioinformatic
22 tools for generating effective viral capture panels, and for assessing coverage of target sequences
23 by probe panel designs *in silico*. In this study, we validated ProbeTools by designing a panel of
24 3,600 probes for subtyping the hypervariable haemagglutinin (HA) and neuraminidase (NA)
25 genome segments of avian-origin influenza A viruses (AIVs). Using *in silico* assessment of AIV
26 reference sequences and *in vitro* capture on egg-cultured viral isolates, we demonstrated
27 effective performance by our custom AIV panel and ProbeTools' suitability for challenging viral
28 probe design applications.

29 **Results:** Based on ProbeTool's *in silico* analysis, our panel provided broadly inclusive coverage
30 of 14,772 HA and 11,967 NA reference sequences. 90% of these HA and NA references
31 sequences had 90.8% and 95.1% of their nucleotide positions covered *in silico* by the panel
32 respectively. We also observed effective *in vitro* capture on a representative collection of 23 egg-
33 cultured AIVs that included isolates from wild birds, poultry, and humans and representatives
34 from all HA and NA subtypes. 42 of 46 HA and NA segments had over 98.3% of their
35 nucleotide positions significantly enriched by our custom panel. These *in vitro* results were

36 further used to validate ProbeTools' *in silico* coverage assessment algorithm; 89.2% of *in silico*
37 predictions were concordant with *in vitro* results.

38 **Conclusions:** ProbeTools generated an effective panel for subtyping AIVs that can be deployed
39 for genomic surveillance, outbreak prevention, and pandemic preparedness. Effective probe
40 design against hypervariable AIV targets also validated ProbeTools' design and coverage
41 assessment algorithms, demonstrating their suitability for other challenging viral capture
42 applications.

43

44 **KEYWORDS**

45 Influenza A viruses, avian influenza viruses, viral genomics, hybridization probe capture,
46 targeted genomic sequencing, viral surveillance

47

48 **BACKGROUND**

49 Most viral specimens are characterized by low amounts of viral genomic material and excessive
50 background from viral hosts and environmental organisms. Consequently, practical viral genome
51 sequencing requires targeted enrichment for confident detection and accurate genotyping,
52 especially in high-throughput surveillance and clinical applications [1-3]. Hybridization probe
53 capture methods have been used for viral target enrichment [4-7], but designing probe oligo
54 sequences for many viruses can be a major obstacle due to extensive genomic diversity and
55 hypervariability within and between viral taxa [8-13].

56 Probe panels are typically designed by enumerating probe-length sub-sequences (k-mers)
57 from reference sequences. The simplest approach to designing probes for hypervariable taxa is to
58 enumerate k-mers from an exhaustive collection of reference sequences, thereby including as

59 much genomic divergence in the design space as possible [7-8]. This approach becomes
60 problematic, however, when redundant probe sequences are enumerated from repeated instances
61 of conserved genomic loci.

62 A few strategies have been used to address this redundancy problem. One common
63 strategy is to cluster similar k-mers after they have been enumerated [6-7]. Another strategy is to
64 align candidate probe sequences against select reference genomes to identify and retain only
65 those probes targeting divergent genotypes [8]. Redundancy has also been addressed by
66 constraining the design space to a limited number of representative reference genomes, selected
67 either by manual curation or clustering [9-12]. Some of these strategies have been supplemented
68 with multiple sequence alignments over hypervariable loci or entire genomes so that probes are
69 designed from consensus and degenerate sequences [9-10].

70 Spacing between probe sequences is another complicated design consideration. Regular
71 spacing (tiling) is the most common approach because it is easy to implement, but it does not
72 ensure optimal positioning of probes. Reducing the spacing increases the likelihood that some
73 enumerated probes are optimally positioned, but it also increases the number of probe candidates
74 and any associated computation to collapse redundancy among them. Creating the smallest
75 possible panel of probes that optimally covers the entire target space quickly becomes an
76 intractable computational problem, one that had led to increasingly complicated approaches
77 including sophisticated minimization of loss functions [13].

78 Efforts to address viral hypervariability have resulted in several elaborate probe design
79 algorithms. Unfortunately, these have largely been implemented on a study-by-study basis and
80 have not resulted in general-purpose software tools that can be easily used by others. Meanwhile,
81 among the handful of published probe design packages, there is only one option that specifically

82 addresses viral hypervariability [13]. The rest are intended for comparatively conserved
83 eukaryotic genomes and are inadequate for many viral applications [14-17]. This leaves
84 virologists with limited options for designing their own hybridization probes, especially if they
85 have minimal capacity for custom programming, sophisticated mathematics, and experimental
86 bioinformatics.

87 Here, we present ProbeTools, a user-friendly command line software package for
88 designing compact probe panels against diverse viral taxa and other hypervariable genomic
89 targets. It provides easy-to-use modules for generating probes and assessing panel coverage of
90 provided target sequences. We demonstrate ProbeTools' effectiveness by designing capture
91 panels for avian-origin influenza A viruses (AIVs). These viruses are subtyped by two
92 hypervariable viral surface proteins called haemagglutinin (HA) and neuraminidase (NA),
93 making them an appropriately challenging case study for ProbeTools. The genome segments
94 encoding these proteins have diversified into 16 avian-origin HA subtypes and 9 avian-origin
95 NA subtypes, giving rise to 144 possible combinations and the HxNx nomenclature used in both
96 animal and human contexts (e.g. H1N1, H3N2, H5N1, H7N9). Furthermore, each of these
97 subtypes has diverged into numerous clades, many of which have been only partially
98 characterized [12, 18-19].

99 AIV lineages have varying potential for spillover from wild birds into poultry and
100 humans [20-25], posing a perennial threat to agriculture and public health. Some lineages cause
101 costly outbreaks of severe disease in poultry flocks which, in turn, expose humans to potentially
102 dangerous zoonotic influenza infections. This threatens economic disruption, future pandemic
103 crises, and new types of seasonal influenza, which remains an important global health burden
104 and among the ten leading causes of death worldwide [12, 21-31]. Consequently, surveillance of

105 AIVs in wild birds is a cornerstone of outbreak prevention and pandemic preparedness [12, 20,
106 32-33]. An effective panel of AIV-specific probes would be instrumental for these genomics-
107 based surveillance efforts.


108 In this study, we designed and validated a compact panel of 3,600 probes for detecting
109 and subtyping AIVs. Our results showed broad inclusivity against all avian-origin HA and NA
110 subtypes based on *in silico* predictions against of tens-of-thousands of AIV reference sequences.
111 We also demonstrated successful captures *in vitro* on a representative collection of 23 egg-
112 cultured AIVs.

113

114 RESULTS

115 **Assessing basic k-mer clustering and marginal improvements to target coverage with
116 additional probes:** We began by assessing probe design against hypervariable targets with a
117 basic k-mer clustering algorithm, wherein all 120-mers were enumerated from a target space of
118 AIV reference sequences then clustered based on 90% nucleotide sequence identity. We used
119 this strategy, implemented in the ProbeTools *clusterkmers* module, to generate probe panels of
120 increasing size against 14,772 HA segment reference sequences and 11,967 NA segment
121 reference sequences. We then used the ProbeTools *capture* module, which aligns probe
122 sequences against target sequences, to assess target space coverage, *i.e.* the percentage of
123 nucleotide positions in each target sequence covered by at least one probe in the panel (Figure
124 1A, solid lines). As expected, panels with more probe sequences provided better target space
125 coverage, however we observed diminishing marginal improvements for both HA and NA
126 genome segments. We also noted that reference sequences with no probe coverage remained in
127 the target space past the point of diminishing marginal returns. These results highlighted two

128 limitations of the basic k-mer clustering approach: HA and NA segments remained undetected
129 despite designing additional probes, and additional probes provided only modest and diminishing
130 improvements to the distribution of target coverage.
131



132

133 **Figure 1: Incremental design strategy improves upon basic k-mer clustering for probe panel design.** Panels
134 were designed against target spaces of 14,772 haemagglutinin (HA) and 11,967 neuraminidase (NA) genome
135 segment reference sequences. The ProbeTools *clusterkmers* module was used to make panels using basic k-mer
136 clustering and the *makeprobes* module was used to make panels with an incremental strategy. For each panel, probe
137 coverage of reference sequences was assessed *in silico* using the ProbeTools *capture* module. A) For both strategies,


138 increasing panel size improved the 10th percentile of reference sequence coverage with diminishing marginal
139 increases, but incrementally designed panels achieved more extensive coverage at larger panel sizes. Incrementally
140 designed panels also provided better coverage of the worst-covered reference sequence using fewer probes. B)
141 Incrementally designed panels shifted coverage distributions upwards for the worst-covered reference sequences.
142 Each reference sequence in the target space is represented as a dot, plotted according to its probe coverage.
143 Coverage of the worst-covered reference sequence and 10th percentile of all reference sequences are indicated above
144 the axis. C) Incrementally designed panels improved reference sequence coverage by re-distributing probes from
145 regions with deep coverage (4 or more probes) to regions with shallow coverage (2 or fewer probes).

146

147 **Improving target coverage with incremental panel design focused on poorly covered**
148 **targets:** To address the limitations we observed with basic k-mer clustering, we devised an
149 incremental design strategy to improve marginal coverage increases, especially for poorly
150 covered targets. In this strategy, basic k-mer clustering was used to design panels in smaller
151 batches of 100 probes. After adding each batch to the growing panel, target space regions
152 without probe coverage were identified using the *capture* module. These low coverage regions
153 were then extracted with another ProbeTools module called *getlowcov* and used as a new target
154 space for designing the next batch. In this way, each subsequent batch of probes was focused on
155 regions not already covered by the panel.

156 We compared target space coverage for panels designed with this incremental strategy
157 against panels designed above using basic k-mer clustering (Figure 1). The incremental strategy
158 provided higher 10th percentiles of coverage, especially for HA panels larger than 2000 probes
159 and NA panels larger than 1200 probes (Figure 1A). Furthermore, the incremental strategy
160 provided better coverage for the worst-covered reference sequences (Figure 1AB). We also
161 compared depth of probe coverage, *i.e.* the number of probes covering each nucleotide position
162 in target sequences (Figure 1C). This comparison suggested that the incremental strategy

163 improved target coverage by redistributing probes from positions with deep coverage to shallow
164 coverage. Based on the observed performance improvements of the incremental strategy, it was
165 implemented as an additional self-contained ProbeTools module called *makeprobes* (Figure 2).
166



167
168 **Figure 2: ProbeTools *makeprobes* module implements a generalized incremental design algorithm.** 1) The user
169 provides a FASTA formatted file containing target sequences, which forms the total target space and become the

170 poorly covered target space for the first loop of the design cycle. 2) The ProbeTools *clusterkmers* module generates
171 a batch of probe sequences from the poorly covered target space using its k-mer clustering algorithm. 3) The latest
172 batch of probes is combined with probes from previous batches to generate the current probe panel. If the size of the
173 current probe panel meets the maximum panel size set by the user, the design loop ends and the current panel
174 becomes the final panel, otherwise... 4) The ProbeTools *capture* module determines which nucleotide positions in
175 the total target space are covered by the current probe panel. 5) The ProbeTools *stats* module calculates the 10th
176 percentile of target coverage from the *capture* module results. If the target coverage goal set by the user is met, the
177 current probe panel becomes the final probe panel, otherwise... 6) The *getlowcov* module extracts low coverage
178 regions of the target space from the *capture* module results. These become the new poorly covered target space, and
179 the design loop repeats.


180

181 **Predicted coverage of HA and NA subtypes by AIV_v1 panel:** Using the incremental strategy
182 implemented in the ProbeTools *makeprobes* module, we generated an AIV-targeting probe panel
183 called AIV_v1. It was composed of 1,935 HA-specific probes and 1,435 NA-specific probes. We
184 also included 184 probes targeting the highly conserved matrix segment (M) which is the
185 standard AIV diagnostic target [24, 38]. We then used the ProbeTools *capture* module to predict
186 probe coverage using the AIV_v1 panel for all 36,313 AIV reference sequences in the target
187 space. The minimum, maximum, and 10th percentile of reference sequence coverage was
188 calculated for each HA and NA subtype and the M segment (Figure 3A).

189 We observed that M segments had the best coverage followed by NA subtypes then HA
190 subtypes, reflecting the comparative levels of genomic diversity within these genome segments.
191 No reference sequence had less than 59.6% coverage, which is sufficient for segment and
192 subtype identification. HA subtypes H5, H7, and H9 are considered high priority for AIV
193 surveillance because they frequently cause agricultural outbreaks and novel influenza infections
194 in humans [23-26, 38]; 90% of H5, H7, and H9 reference sequences had at least 94.4%, 88.5%,

195 and 92.4% probe coverage respectively. We also noted a significant positive monotonic
196 association between a subtype's target coverage distribution and number of reference sequences
197 from that subtype in the target space (Figure 3B). This indicated that over-representing subtypes
198 in the target space resulted in preferential design and better probe coverage for these targets, *e.g.*
199 the high priority subtypes H5, H7, and H9.

200



201

202 **Figure 3: The ProbeTools-designed AIV_v1 panel provided broadly inclusive coverage *in silico* of avian-
203 origin HA subtypes, NA subtypes, and M segments.** The AIV_v1 panel of 3,600 probes was designed using the
204 ProbeTools *makeprobes* module. It was composed of 1,935 haemagglutinin (HA) segment-specific, 1,435
205 neuraminidase (NA) segment-specific, and 184 matrix (M) segment-specific probes. A) Coverage predictions

206 against 36,313 reference sequences were generated with the ProbeTools *capture* module and stratified by subtype
207 for HA and NA segments. The minimum, 10th percentile, and maximum of probe coverage against reference
208 sequences from each subtype/segment are indicated. B) A significant positive monotonic association was observed
209 between the number of sequences from a subtype in the target space and that subtype's 10th percentile of coverage.
210 Each dot represents an HA or NA subtype, and the results of Spearman's rank correlation test are indicated on the
211 plots.

212

213 ***In vitro* capture of diverse egg-cultured influenza isolates:** After assessing the AIV_v1 panel
214 *in silico*, we had it synthesized and used it to perform *in vitro* captures on a collection of diverse
215 egg-cultured AIV isolates (Table 1). We ensured that each avian-origin HA and NA subtype was
216 represented in the collection, and we included isolates from wild birds, poultry, and humans. The
217 collection contained 22 egg cultures, including one mixed infection, providing 23 viruses and 69
218 distinct HA, NA, and M segments for *in vitro* capture.

219

220 **Table 1: Representative collection of egg-cultured avian influenza virus isolates.** Isolates were selected to
221 provide representation of each avian-origin haemagglutinin (HA) and neuraminidase (NA) subtype as well as
222 infections from poultry, wild bird, and human hosts. Each specimen was given a name based on an abbreviation of
223 its host type and a sequential number (P for poultry, WB for wild bird, and H for human). Poultry and wild bird
224 isolates were obtained from the Canadian Food Inspection Agency's National Centre for Foreign Animal Disease
225 (CFIA NCFAD), and human isolates were obtained from the Public Health Agency of Canada's National
226 Microbiology Laboratory (PHAC NML). Isolate subtypes were confirmed in-house by genome sequencing.

Specimen name	Host type	Strain name	HA subtype	NA subtype	Source laboratory
P1	Poultry	A/Turkey/Ontario/844-2/2006	H6	N1	CFIA NCFAD
P2	Poultry	A/Chicken/Germany/N/1949	H10	N7	
P3	Poultry	A/Turkey/Ontario/18-2/2000	H7	N1	
P4	Poultry	A/Emu/Texas/39924/1993	H5	N2	
P5	Poultry	A/Turkey/Ontario/6118/1967	H8	N4	
P6	Poultry	A/Chicken/Quebec/IM-109/2010	H6	N1	
WB1	Wild bird	A/Duck/British Columbia/26-2/2005	H5	N2	


WB2	Wild bird	A/Swan/Alberta/OTH33-8/2009	H1	N1	
WB3	Wild bird	A/Teal/Germany/Wv632/2005	H5	N1	
WB4	Wild bird	A/Duck/Alberta/C-16/2007	H7	N7	
WB5	Wild bird	A/Duck/Australia/341/1983	H15	N8	
WB6	Wild bird	A/Duck/Alberta/60/1976	H12	N5	
WB7	Wild bird	A/Gull/Maryland/4/1977	H13/H7	N6/N3	
WB8	Wild bird	A/Pheasant/Washington/37349/1985	H9	N9	
WB9	Wild bird	A/Mallard/Gurjev/263/1982	H14	N5	
WB10	Wild bird	A/Duck/British Columbia/14/1999	H4	N6	
WB11	Wild bird	A/Duck/Prince Edward Island/274.1/2006	H16	N3	
WB12	Wild bird	A/Duck/Alberta/431/2006	H3	N8	
WB13	Wild bird	A/Pintail/Alberta/293/1977	H2	N9	
WB14	Wild bird	A/Mallard/Manitoba/OTH27-1186/2017	H11	N9	
H1	Human	A/Alberta/01/2014	H5	N1	PHAC
H2	Human	A/Anhui/1/2013	H7	N9	NML

227

228 Sequencing libraries were prepared from each isolate then pooled. AIV library pools
229 were diluted 1:100 (ng/ng) in libraries of background material made from mock-infected egg
230 cultures, then captured three times independently using the AIV_v1 panel. Pre- and post-capture
231 pools were sequenced to calculate mean fold-enrichment at each nucleotide position in these 69
232 HA, NA, and M segments. Half of all nucleotide positions had a mean fold-enrichment greater
233 than 351.2-fold, and 90% of nucleotide positions had a mean fold-enrichment greater than 195.0-
234 fold (Figure 4A). We also calculated the percentage of the capture pools composed of
235 background material from the mock-infected egg cultures, then compared these percentages pre-
236 and post-capture (Figure 4B). Before capture, the mean background percentage was 99.17%, but
237 this was reduced to 0.03% following capture. Together, these data demonstrate effective

238 enrichment of AIV material and removal of background by probe capture with the AIV_v1
239 panel.

240




241
242 **Figure 4: Effective *in vitro* capture of egg-cultured avian influenza virus isolates using the ProbeTools-
243 designed AIV_v1 panel.** The AIV_v1 panel of 3,600 probes was designed using ProbeTools, and it was used to
244 capture sequencing libraries made from a representative collection of 23 egg-cultured avian influenza viruses (AIVs)
245 (described in Table 1). AIV libraries were pooled together, diluted 1:100 (ng/ng) in libraries of background material
246 made from mock-infected egg cultures, then captured three times independently. A) Pre- and post-capture pools
247 were sequenced to calculate fold-enrichment at each nucleotide position in the haemagglutinin (HA), neuraminidase
248 (NA), and matrix (M) genome segments of these isolates (mean of three independent replicates). B) Background
249 material from mock-infected egg cultures was effectively removed during probe capture. C) Breadth of enrichment,
250 *i.e.* the percentage of nucleotide positions that were significantly enriched by probe capture, was calculated for each
251 HA, NA, and M genome segment in these isolates.

252

253 We also used these *in vitro* results to assess breadth of enrichment, *i.e.* the percentage of
254 nucleotide positions in each HA, NA, and M segment that had been significantly enriched by
255 probe capture (Figure 4C, Table S1). Breadth of enrichment was greater than 96.3% for 64 of 69
256 segments in the collection, and it was not less than 46.5% for any segment, which is sufficient
257 for segment and subtype identification. Nine isolates contained high priority H5, H7, and H9
258 segments, all of which had greater than 98.7% breadth of enrichment. This included two isolates
259 from zoonotic human infections (H5N1 and H7N9), which were extensively enriched despite the
260 absence of reference sequences from human infections in the target space used for probe design.

261 We further examined the five segments with less than 96.3% breadth of enrichment to
262 understand why they were apparently not captured in full. First, we used the ProbeTools *capture*
263 module to assess if the AIV_v1 panel lacked probes targeting their particular genome segment
264 sequences. We observed that most positions without significant enrichment were nonetheless
265 extensively covered by the probe panel (Figure 5A). This indicated that insufficient design by
266 ProbeTools was not a major explanation for the lack of significant capture of these segments.

267



268

269 **Figure 5: Lack of significant enrichment in segments with lower breadths of enrichment was due to**
270 **experimental variation between capture replicates instead of insufficient probe design.** A representative
271 collection of 23 egg-cultured avian influenza viruses was captured three times independently using the ProbeTools-
272 designed AIV_v1 panel. A) ProbeTools *capture* was used to predict probe panel coverage of positions without
273 significant enrichment from 5 genome segments with breadths of enrichment less than 96%. These positions were
274 extensively targeted by probes in the AIV_v1 panel. B) Fold-enrichment was comparable for positions with and
275 without significant enrichment. The difference in distribution means was only 1.09-fold, although it was statistically
276 significantly ($p < 0.0001$, Welch's t-test) due to the large number of nucleotide positions involved in the comparison
277 ($n = 96,376$ and $n = 3,082$ for positions with and without significant enrichment respectively). C) Variation in fold-

278 enrichment between three independent replicates was significantly higher for positions that did not achieve
279 significant enrichment ($p < 0.0001$, Levene's test). D) Most positions with insignificant enrichment narrowly failed
280 the enrichment test's pre-determined alpha level of 5%.

281

282 Next, we assessed whether experimental factors were responsible for nucleotide positions
283 in these segments failing to achieve statistically significant enrichment. Fold-enrichment values
284 between positions with and without significant enrichment were comparable, but variation
285 between capture replicates were significantly different, with higher variation for positions that
286 were not significantly enriched (Figure 5BC). Despite this source of experimental variation, and
287 the limited number of replicates that was practical for us to perform, only 3.1% of nucleotide
288 positions across all HA, NA, and M segments were impacted, and most of these positions only
289 barely failed the enrichment significance test (half achieved a p -value < 0.07) (Figure 5D).
290 Overall, our *in vitro* capture results demonstrated that the ProbeTools-designed AIV_v1 panel
291 performed well on real viral isolates, effectively removing background material and providing
292 high breadths of enrichment across HA, NA, and M segment targets.

293

294 **Comparison of *in silico* probe coverage prediction and *in vitro* probe capture enrichment:**
295 ProbeTools relies on *in silico* coverage assessment by the *capture* module, both for final panel
296 evaluation and for identifying poorly covered sequences during incremental design. To validate
297 ProbeTools' coverage assessment algorithm, we examined how closely its *in silico* predictions
298 agreed with *in vitro* capture results on egg-cultured AIV isolates.

299

		Significantly enriched		
		False	True	Total
Targeted by panel	False	761 (0.8%)	7,678 (7.7%)	8,439 (8.5%)
	True	2,321 (2.3%)	88,698 (89.2%)	91,019 (91.5%)
	Total	3,082 (3.1%)	96,376 (96.9%)	99,458 (100.0%)

300

301 **Figure 6: *In silico* predictions of probe coverage by ProbeTools were highly concordant with actual *in vitro***

302 enrichment of egg-cultured AIV isolates.

303 A representative collection of 23 egg-cultured avian influenza viruses

304 was captured three times independently using the ProbeTools-designed AIV_v1 panel. Pre- and post-capture pools

305 were sequenced to determine which nucleotide positions in the haemagglutinin (HA), neuramindase (NA), and

306 matrix (M) genome segments of these isolates had been significantly enriched. The ProbeTools *capture* module was

307 used to assess which nucleotide positions of these HA, NA, and M genome segments were targeted by the

308 ProbeTools-designed panel. Each cell indicates the number of nucleotide positions meeting the corresponding *in*

309 *silico* prediction and *in vitro* capture conditions.

309

310 Using the ProbeTools *capture* module, we determined which nucleotide positions in the

311 egg-cultured AIVs were predicted to be covered by the AIV_v1 probe panel. We then compared

312 these predictions to our *in vitro* capture results to see if significant enrichment had actually

313 occurred at these nucleotide positions (Figure 6). Predicted probe coverage and significant

314 enrichment results were concordant for 89.2% of nucleotide positions. Only 2.3% of nucleotide

315 positions targeted by the AIV_v1 panel were not significantly enriched. These were concentrated

316 in the five segments discussed above that were impacted by variability between replicates

317 (Figure S1). We also noted that 7.7% of nucleotide positions were significantly enriched despite

318 not being targeted by the AIV_v1 panel, a phenomenon that was observed in most segments
319 across all isolates (Figure 6 and Figure S1). We attribute this to the capture of larger fragments
320 containing untargeted sequences adjacent to the location annealed by the probe. It might also
321 indicate that local alignment parameters used by ProbeTools *capture* are more conservative than
322 actual annealing thermodynamics. Either way, these results showed that ProbeTools predictions
323 generally reflected actual capture of target genomic material, and *in silico* predictions more often
324 underestimated panel performance when predictions were incorrect.

325

326 **DISCUSSION**

327 This study highlighted some important considerations when designing panels using ProbeTools.
328 Foremost among these was the effect of target space composition on panel inclusivity. In this
329 AIV case study, we noted a significant positive monotonic association between panel coverage
330 and the number of reference sequences representing a particular subtype in the target space.
331 Based on how the ProbeTools algorithm ranks probe candidates by the number of k-mers in the
332 cluster they represent, it stands to reason that over-representing similar taxa (which would
333 contain many similar k-mers) would bias the resulting panel towards these taxa.

334 Consequently, ProbeTools users should have a thorough knowledge of the contents of
335 their target space and the possible sources of sampling bias in the databases from which they
336 obtain their reference sequences. In the case of AIVs, the agricultural impacts and public health
337 threats of certain HA subtypes have led to more frequent sequencing of these subtypes and
338 accessioning of their genome sequences in popular databases. For our panel, this contributed to
339 bias towards subtypes like H5, H7 and H9. Whether this is a benefit or limitation will depend on
340 the intended application. In the context of outbreak prevention and pandemic preparedness, a

341 panel biased towards taxa that are known for their agricultural impact and zoonotic potential is
342 beneficial. If the objective is to characterize viral diversity and ecology in wildlife, however, this
343 could be a limitation.

344 To obtain the best results, ProbeTools users should purposefully curate their target space
345 to serve their probe capture objectives. Users may want to identify taxa whose detection is a
346 priority and over-represent them in the target space. Conversely, users may want to ‘flatten’ their
347 target space to ensure no particular taxa, clades, subtypes, *etc* dominate. This could be done
348 manually, by selecting specific sequences to represent relevant groups, or it could be attempted
349 bioinformatically by pre-clustering target sequences, providing the number and length of target
350 sequences do not make this computationally prohibitive.

351 Another strategy could be to use the various ProbeTools modules to extract low coverage
352 sequences from specific groups whose target sequences have poor probe coverage after a core
353 panel is designed. For instance, had H15 subtype AIVs been a surveillance priority in this study,
354 supplemental H15-specific probes could have been designed by running the *capture*, *getlowcov*,
355 and *makeprobes* modules on the H15 subset of target sequences after noting their comparatively
356 low coverage by the main panel. In this way, the modular nature of ProbeTools and the relatively
357 simple-to-understand algorithms within each module empower users to experiment and find
358 creative solutions. This flexibility is instrumental for tailoring probe panels to the needs of the
359 user and their specific viral capture application.

360

361 CONCLUSIONS

362 In this study, we used ProbeTools to create an effective and broadly inclusive panel of
363 hybridization capture probes for subtyping AIVs. Our results show the utility of this panel as a

364 tool for AIV surveillance, outbreak prevention, and pandemic preparedness. They also
365 demonstrate that ProbeTools can effectively design probes against hypervariable genomic targets
366 like avian-origin HA and NA segments. This validation of ProbeTools' core design and coverage
367 assessment algorithms shows that they are suitable for other challenging design applications, *e.g.*
368 other viruses with hypervariable genes and pan-viral capture panels targeting multiple diverse
369 taxa.

370 An increasing frequency of zoonotic outbreaks, epidemics, and pandemic crises has
371 renewed interest in characterizing viral diversity at the interface of wildlife, livestock, game, and
372 humans [39-42]. Genomic sequencing is becoming central to these One Health ventures, and
373 viral capture panels will need designing and updating as our knowledge of viral threats continues
374 to expand [43-44]. The on-going COVID-19 pandemic has also demonstrated the value of viral
375 genomics to public health [45-48], resulting in unprecedented investments in sequencing
376 capacity at public health laboratories. This will expand routine genomics for numerous common
377 pathogens, requiring the development of new target enrichment protocols. ProbeTools can
378 facilitate probe design tasks for all of these endeavours.

379

380 METHODS

381 **ProbeTools modules:** ProbeTools consists of five main modules written in Python (v3.7.3) that
382 perform essential tasks in the probe design process. ProbeTools is freely available under the MIT
383 License. It can be installed easily using the Anaconda/Miniconda package and environment
384 manager. Alternatively, it can be installed via the Python Package Index, followed by separate
385 installation of its VSEARCH and BLASTn dependencies. Installation instructions, source code,

386 documentation, and usage examples are available at

387 <https://github.com/KevinKuchinski/ProbeTools>.

388 The *clustermers* module enumerates and clusters probe-length k-mers from user-
389 provided target sequences. 1) K-mers are enumerated using a sliding window that advances by a
390 specified number of bases. 2) K-mers are clustered based on nucleotide sequence similarity using
391 VSEARCH cluster_fast [34]. 3) Centroid sequences from each cluster are ranked by the size of
392 the cluster they represent. Centroids from larger clusters are assumed to be better probe
393 candidates by virtue of having similarity to more k-mers in the target space. By default,
394 *clustermers* enumerates 120-mers, advancing the window one base at a time, and it clusters
395 using a nucleotide sequence identity threshold of 90%. Previous studies have observed effective
396 hybridization between targets and probes with this degree of sequence similarity [9, 11].

397 The *capture* module predicts how well user-provided probe sequences cover user-
398 provided target sequences. 1) Each probe sequence is locally aligned against each target
399 sequence using BLASTn [35]. 2) Alignments are filtered, retaining those with a minimum
400 sequence identity over a minimum alignment length. 3) Subject alignment start and end
401 coordinates are extracted from the BLASTn results to determine which nucleotide positions in
402 the target sequences are covered by probes. By default, *capture* requires 90% sequence identity
403 over at least 60 bases to assign probe coverage to the aligned positions.

404 The *getlowcov* module uses the output of *capture* to extract genomic regions with low
405 coverage from the provided targets. This allows for additional probe design focused on poorly
406 covered regions of the target space. This module returns all sub-sequences where a minimum
407 number of consecutive bases were covered by fewer than a specified number of probes. By

408 default, *getlowcov* returns all sub-sequences over 40 bases in length where all bases in the sub-
409 sequence were covered by zero probes.

410 The *stats* module uses the output of *capture* to calculate coverage statistics. For each
411 provided target, it calculates the percentage of nucleotide positions covered by varying numbers
412 of probes (“target coverage” and “probe depth”).

413 The *makeprobes* module chains the previous modules together to implement a
414 generalized incremental design strategy (Figure 2). In this strategy, probes are designed in
415 batches, and regions of the target space with probe coverage are removed between batches so
416 that additional probes are focused on poorly covered areas. This module can be used as a
417 convenient departure point for custom designs. The user is only required to provide target
418 sequences and select a batch size. They can optionally specify a maximum panel size and target
419 space coverage goal. The *makeprobes* module iterates through its design loop, adding batches of
420 probes to the panel until the maximum panel size is met, the target space coverage goal is
421 achieved, or no further probes can be generated.

422

423 **Preparation of AIV target space:** All available full-length influenza A virus genome segment
424 sequences from avian hosts were downloaded from the Influenza Research Database
425 (www.fludb.org) on Dec 5, 2017 [36]. Sequences containing degenerate bases were removed to
426 avoid low quality entries. Sequences were then clustered using VSEARCH cluster_fast (v1.0.7)
427 [34] with a 100% sequence identity threshold to remove redundant entries. The remaining entries
428 were used as our final AIV target space (described in Table 2).

429

430 **Table 2: Avian influenza virus reference sequences used as target space in this study.** Full-length genome
431 segment sequences from avian hosts were downloaded from the Influenza Research Database (www.fludb.org).

432 Sequences containing degenerate bases were removed, then the remaining sequences were clustered using a 100%
433 nucleotide sequence identity threshold to discard redundant entries. This provided a final target space of 36,313
434 reference sequences representing all avian-origin haemagglutinin (HA) subtypes, neuraminidase (NA) subtypes, and
435 matrix (M) segments.

Genome segment	Subtype	Reference sequences in target space (#)	Target space size (KB)
HA	H1	539	939.1
	H2	381	664.0
	H3	1,309	2,267.6
	H4	1,135	1,944.1
	H5	3,546	6,129.7
	H6	1,378	2,361.3
	H7	1,266	2,148.5
	H8	122	209.9
	H9	2,653	4,498.9
	H10	591	1,005.4
	H11	520	897.5
	H12	176	301.5
	H13	232	405.4
	H14	22	38.3
	H15	13	22.7
	H16	156	271.7
	HA untyped	733	1,254.8
	HA total	14,772	25,360.4
NA	N1	2,742	3,804.9
	N2	3,162	4,498.5
	N3	945	1,347.3
	N4	174	249.8
	N5	296	427.4
	N6	1,424	2,037.0
	N7	502	718.4
	N8	1,272	1,822.9
	N9	667	948.5
	NA untyped	783	1,116.6
	NA total	11,967	16,971.0
M	none	9,574	9,582.4

436

437 **AIV_v1 probe panel design:** The AIV_v1 panel was designed against our final AIV target
438 space using the ProbeTools *makeprobes* module as follows: 2,000 probes were designed against
439 HA targets in 20 batches of 100 probes; 1,500 probes were designed against NA targets in 15
440 batches of 100 probes, and 200 probes were designed against M targets in 20 batches of 10

441 probes. All designs were conducted using *makeprobes*'s default parameters with ProbeTools
442 v0.0.5, VSEARCH v1.0.7, and BLASTn v2.2.31.

443 The top-ranked 1,935 HA probes, 1,435 NA probes, and 184 M probes were combined
444 into the final panel. Additional probes were added to the panel for potential control and
445 validation applications, including 36 probes targeting the common reference strain A/Puerto
446 Rico/8/34 and 10 probes targeting synthetic spike-in DNA oligomers with randomly generated
447 artificial sequences. This provided a final panel of 3,600 probes (a breakpoint in the
448 manufacturer's pricing structure), which was synthesized as a custom panel by Twist Bioscience
449 (San Francisco, CA, USA). Sequences for probes in the AIV_v1 panel are provided in
450 Supplemental Material 1.

451
452 **Preparation of sequencing libraries from egg-cultured influenza isolates:** Detailed laboratory
453 procedures for the following are provided in Supplemental Material 2. RNA extracted from egg-
454 cultured AIV isolates was provided by the Canadian Food Inspection Agency's National Centre
455 for Foreign Animal Disease (Winnipeg, Manitoba, Canada) and the Public Health Agency of
456 Canada's National Microbiology Laboratory (Winnipeg, Manitoba, Canada). cDNA was
457 prepared from each isolate using a previously described method [37]. cDNA was also prepared
458 from a mock-infected egg culture to generate background genomic material for diluting capture
459 pools. cDNA was fragmented by sonication, then prepared into sequencing libraries for Illumina
460 platforms with unique dual index barcodes. Adapter-ligated cDNA was split into three separate
461 barcoding reactions, providing three separately barcoded replicate libraries for each isolate.

462

463 **Probe capture enrichment and genomic sequencing of libraries prepared from egg-cultured**
464 **influenza isolates:** Detailed laboratory and bioinformatic procedures for the following are
465 provided in Supplemental Material 2. 1) Three pools were prepared, with each pool containing
466 one replicate library from each AIV isolate. These pools were sequenced in-house on Illumina
467 MiSeq to generate full HA, NA, and M segment sequences for each isolate and to confirm HA
468 and NA subtypes. 2) Each pool was diluted in 1:100 (ng/ng) in one of three replicate libraries of
469 background genomic material that had been prepared from a mock-infected chicken egg.
470 Aliquots of each diluted pool were sequenced pre-capture at Canada's Michael Smith Genome
471 Sciences Centre (Vancouver, BC) on one Illumina HiSeq X lane to establish baseline HA, NA,
472 and M segment abundance. 3) Each diluted pool was independently captured using the AIV_v1
473 probe panel. Captured pools were then sequenced in-house on Illumina MiSeq to assess target
474 enrichment of HA, NA, and M segments post-capture.

475
476 **Analysis of significant probe capture enrichment for egg-cultured AIV isolates:** 1) Pre- and
477 post-capture depths of coverage were determined by mapping each library's sequencing reads to
478 the HA, NA, and M segment sequences of its corresponding AIV isolate. 2) Depths of coverage
479 were normalized by dividing raw pre- and post-capture read depths by the total reads in the
480 corresponding pre- and post-capture pools (Table S2). 3) For each library, fold-enrichment at
481 each nucleotide position was calculated by dividing the normalized post-capture read depth by
482 the normalized pre-capture read depth. 4) For each AIV isolate, mean fold-enrichment was
483 calculated at every nucleotide position from the fold-enrichment values of its three independently
484 captured replicate libraries. 5) Mean fold-enrichment values and their standard deviations were

485 used to determine if significant enrichment had occurred at all nucleotide positions using a one-
486 sample T-test against the fixed value of one-fold enrichment with an alpha level of 5%.

487

488 DECLARATIONS

489 **Ethics approval and consent to participate:** Not applicable.

490

491 **Consent for publication:** Not applicable.

492

493 **Availability of data and materials:** ProbeTools v0.0.5 source code, which was used to design
494 the final probe panel and assess its coverage of target sequences *in silico* for this manuscript, is
495 available on GitHub at <https://github.com/KevinKuchinski/ProbeTools>. FASTA files of the HA,
496 NA, and M genome segment reference sequences used as a target space for design and
497 assessment in this manuscript (described in Table 2) are provided as part of the ProbeTools
498 v0.0.5 release. The sequences of the AIV_v1 probe panel are also provided as part of the
499 ProbeTools v0.0.5 release, and they are also included in this manuscript's supplemental
500 information as Supplemental Material 1. Data from the *in vitro* captures are provided in BAM
501 format with pre- and post-capture libraries mapped to the HA, NA, and M genome segment
502 sequences of their corresponding egg-cultured AIV isolate. These can be accessed from the
503 NCBI Short Read Archive as part of BioProject PRJNA796698. Total read counts used to
504 normalize depths of coverage in these libraries are provided in the manuscript's supplemental
505 material as Table S2.

506

507 **Competing interests:** The authors declare that they have no competing interests.

508

509 **Funding:** This work was funded through research grants from Genome British Columbia
510 (UPP025), Investment Agriculture Foundation of British Columbia (A0822), and the CANARIE
511 Research Software Program (RS3-073).

512

513 **Authors' contributions:** KK designed and implemented the ProbeTools algorithms, wrote the
514 ProbeTools source code, designed the AIV_v1 probe panel, prepared sequencing libraries,
515 performed probe captures and in-house sequencing, analyzed the data, and wrote the manuscript.
516 JD performed preliminary studies with k-mer clustering, assisted with the design and
517 implementation of the ProbeTools algorithms, and provided guidance on bioinformatic data
518 analysis. CH helped assemble the validation collection of egg-cultured AIV isolates, ensured
519 relevant strains were included, and provided direction for AIV probe panel design to ensure its
520 suitability for agricultural surveillance applications. WH provided guidance on implementing
521 ProbeTools algorithms, best practices for constructing and distributing bioinformatics tools and
522 packages, and bioinformatic data analysis. NP provided guidance on experiment design for *in*
523 *vitro* captures, troubleshooting for library preparation, probe capture, and sequencing of egg-
524 cultured AIV isolates, and provided direction for AIV probe panel design to ensure its suitability
525 for public health surveillance applications. All authors reviewed and contributed comments on
526 the manuscript.

527

528 **Acknowledgements:** We would like to acknowledge the efforts of all laboratories world-wide
529 who have submitted genomic sequences to the Influenza Research Database. Dr. Yohannes
530 Berhane and Matthew Suderman at the Canadian Food Inspection Agency's National Centre for

531 Animal Disease were instrumental in providing diverse egg-cultured AIV validation material
532 from wild birds and poultry. We also thank Dr. Agatha Jassem at the British Columbia Centre for
533 Disease Control's Public Health Laboratory and Dr. Nathalie Bastien at the Public Health
534 Agency of Canada's National Microbiology Laboratory for providing H5N1 and H7N9
535 validation material from human infections. Additionally, we thank Tracy Lee at the British
536 Columbia Centre for Disease Control's Public Health Laboratory for providing primers used to
537 generate cDNA from AIV egg-cultures.

538

539 REFERENCES

- 540 1. Fitzpatrick AH, Rupnik A, O'Shea H, Crispie F, Keaveney S, Cotter P. High Throughput
541 Sequencing for the Detection and Characterization of RNA Viruses. *Front Microbiol*. 2021
542 Feb 22;12:621719.
- 543 2. Xiao M, Liu X, Ji J, Li M, Li J, Yang L, Sun W, Ren P, Yang G, Zhao J, Liang T, Ren H,
544 Chen T, Zhong H, Song W, Wang Y, Deng Z, Zhao Y, Ou Z, Wang D, Cai J, Cheng X, Feng
545 T, Wu H, Gong Y, Yang H, Wang J, Xu X, Zhu S, Chen F, Zhang Y, Chen W, Li Y, Li J.
546 Multiple approaches for massively parallel sequencing of SARS-CoV-2 genomes directly
547 from clinical samples. *Genome Med*. 2020 Jun 30;12(1):57.
- 548 3. Houldcroft CJ, Beale MA, Breuer J. Clinical and biological insights from viral genome
549 sequencing. *Nat Rev Microbiol*. 2017 Mar;15(3):183-192.
- 550 4. Depledge DP, Palser AL, Watson SJ, Lai IY, Gray ER, Grant P, Kanda RK, Leproust E,
551 Kellam P, Breuer J. Specific capture and whole-genome sequencing of viruses from clinical
552 samples. *PLoS One*. 2011;6(11):e27805.

553 5. Paskey AC, Frey KG, Schroth G, Gross S, Hamilton T, Bishop-Lilly KA. Enrichment post-
554 library preparation enhances the sensitivity of high-throughput sequencing-based detection
555 and characterization of viruses from complex samples. *BMC Genomics*. 2019 Feb
556 26;20(1):155.

557 6. Brown JR, Roy S, Ruis C, Yara Romero E, Shah D, Williams R, Breuer J. Norovirus Whole-
558 Genome Sequencing by SureSelect Target Enrichment: a Robust and Sensitive Method. *J
559 Clin Microbiol*. 2016 Oct;54(10):2530-7.

560 7. Wylezich C, Calvelage S, Schlottau K, Ziegler U, Pohlmann A, Höper D, Beer M. Next-
561 generation diagnostics: virus capture facilitates a sensitive viral diagnosis for epizootic and
562 zoonotic pathogens including SARS-CoV-2. *Microbiome*. 2021 Feb 20;9(1):51.

563 8. Wylie TN, Wylie KM, Herter BN, Storch GA. Enhanced virome sequencing using targeted
564 sequence capture. *Genome Res*. 2015 Dec;25(12):1910-20.

565 9. O'Flaherty BM, Li Y, Tao Y, Paden CR, Queen K, Zhang J, Dinwiddie DL, Gross SM,
566 Schroth GP, Tong S. Comprehensive viral enrichment enables sensitive respiratory virus
567 genomic identification and analysis by next generation sequencing. *Genome Res*. 2018
568 Jun;28(6):869-877.

569 10. Bonsall D, Ansari MA, Ip C, Trebes A, Brown A, Klenerman P, Buck D; STOP-HCV
570 Consortium, Piazza P, Barnes E, Bowden R. ve-SEQ: Robust, unbiased enrichment for
571 streamlined detection and whole-genome sequencing of HCV and other highly diverse
572 pathogens. *F1000Res*. 2015 Oct 13;4:1062.

573 11. Briese T, Kapoor A, Mishra N, Jain K, Kumar A, Jabado OJ, Lipkin WI. Virome Capture
574 Sequencing Enables Sensitive Viral Diagnosis and Comprehensive Virome Analysis. *mBio*.
575 2015 Sep 22;6(5):e01491-15.

576 12. Xiao Y, Nolting JM, Sheng ZM, et al. Design and validation of a universal influenza virus
577 enrichment probe set and its utility in deep sequence analysis of primary cloacal swab
578 surveillance samples of wild birds. *Virology*. 2018;524:182-191.

579 13. Metsky HC, Siddle KJ, Gladden-Young A, Qu J, Yang DK, Brehio P, Goldfarb A, Piantadosi
580 A, Wohl S, Carter A, Lin AE, Barnes KG, Tully DC, Corleis B, Hennigan S, Barbosa-Lima
581 G, Vieira YR, Paul LM, Tan AL, Garcia KF, Parham LA, Odia I, Eromon P, Folarin OA,
582 Goba A; Viral Hemorrhagic Fever Consortium, Simon-Lorière E, Hensley L, Balmaseda A,
583 Harris E, Kwon DS, Allen TM, Runstadler JA, Smole S, Bozza FA, Souza TML, Isern S,
584 Michael SF, Lorenzana I, Gehrke L, Bosch I, Ebel G, Grant DS, Happi CT, Park DJ, Gnrke
585 A, Sabeti PC, Matranga CB. Capturing sequence diversity in metagenomes with
586 comprehensive and scalable probe design. *Nat Biotechnol*. 2019 Feb;37(2):160-168.

587 14. Chafin TK, Douglas MR, Douglas ME. MrBait: universal identification and design of
588 targeted-enrichment capture probes. *Bioinformatics*. 2018 Dec 15;34(24):4293-4296.

589 15. Beliveau BJ, Kishi JY, Nir G, Sasaki HM, Saka SK, Nguyen SC, Wu CT, Yin P. OligoMiner
590 provides a rapid, flexible environment for the design of genome-scale oligonucleotide in situ
591 hybridization probes. *Proc Natl Acad Sci U S A*. 2018 Mar 6;115(10):E2183-E2192.

592 16. Mayer C, Sann M, Donath A, Meixner M, Podsiadlowski L, Peters RS, Petersen M,
593 Meusemann K, Liere K, Wägele JW, Misof B, Bleidorn C, Ohl M, Niehuis O. BaitFisher: A
594 Software Package for Multispecies Target DNA Enrichment Probe Design. *Mol Biol Evol*.
595 2016 Jul;33(7):1875-86.

596 17. Kushwaha SK, Manoharan L, Meerupati T, Hedlund K, Ahrén D. MetCap: a bioinformatics
597 probe design pipeline for large-scale targeted metagenomics. *BMC Bioinformatics*. 2015 Feb
598 28;16(1):65.

599 18. Dugan VG, Chen R, Spiro DJ, et al. The evolutionary genetics and emergence of avian
600 influenza viruses in wild birds. *PLoS Pathog.* 2008;4(5):e1000076. Published 2008 May 30.

601 19. Wille M, Tolf C, Avril A, Latorre-Margalef N, Wallerström S, Olsen B, Waldenström J.
602 Frequency and patterns of reassortment in natural influenza A virus infection in a reservoir
603 host. *Virology.* 2013 Aug 15;443(1):150-60. doi: 10.1016/j.virol.2013.05.004. Epub 2013
604 May 28.

605 20. Verhagen JH, Fouchier RAM, Lewis N. Highly Pathogenic Avian Influenza Viruses at the
606 Wild-Domestic Bird Interface in Europe: Future Directions for Research and
607 Surveillance. *Viruses.* 2021;13(2):212. Published 2021 Jan 30.

608 21. Widdowson MA, Bresee JS, Jernigan DB. The Global Threat of Animal Influenza Viruses of
609 Zoonotic Concern: Then and Now. *J Infect Dis.* 2017;216(suppl_4):S493-S498.

610 22. Mostafa A, Abdelwhab EM, Mettenleiter TC, Pleschka S. Zoonotic Potential of Influenza A
611 Viruses: A Comprehensive Overview. *Viruses.* 2018;10(9):497. Published 2018 Sep 13.

612 23. Sutton TC. The Pandemic Threat of Emerging H5 and H7 Avian Influenza Viruses. *Viruses.*
613 2018;10(9):461. Published 2018 Aug 28.

614 24. Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. *Clin
615 Microbiol Rev.* 2007;20(2):243-267.

616 25. Watanabe T, Watanabe S, Maher EA, Neumann G, Kawaoka Y. Pandemic potential of avian
617 influenza A (H7N9) viruses. *Trends Microbiol.* 2014;22(11):623-631.

618 26. Nuñez IA, Ross TM. A review of H5Nx avian influenza viruses. *Ther Adv Vaccines
619 Immunother.* 2019;7:2515135518821625. Published 2019 Feb 22.

620 27. Macias AE, McElhaney JE, Chaves SS, Nealon J, Nunes MC, Samson SI, Seet BT, Weinke
621 T, Yu H. The disease burden of influenza beyond respiratory illness. *Vaccine*. 2021 Mar
622 15;39 Suppl 1:A6-A14.

623 28. Lafond KE, Porter RM, Whaley MJ, Suizan Z, Ran Z, Aleem MA, Thapa B, Sar B, Proschle
624 VS, Peng Z, Feng L, Coulibaly D, Nkwembe E, Olmedo A, Ampofo W, Saha S, Chadha M,
625 Mangiri A, Setiawaty V, Ali SS, Chaves SS, Otorbaeva D, Keosavanh O, Saleh M, Ho A,
626 Alexander B, Oumzil H, Baral KP, Huang QS, Adebayo AA, Al-Abaidani I, von Horoch M,
627 Cohen C, Tempia S, Mmbaga V, Chittaganpitch M, Casal M, Dang DA, Couto P, Nair H,
628 Bresee JS, Olsen SJ, Azziz-Baumgartner E, Nuorti JP, Widdowson MA; Global Respiratory
629 Hospitalizations–Influenza Proportion Positive (GRIPP) Working Group. Global burden of
630 influenza-associated lower respiratory tract infections and hospitalizations among adults: A
631 systematic review and meta-analysis. *PLoS Med*. 2021 Mar 1;18(3):e1003550.

632 29. Gordon A, Reingold A. The Burden of Influenza: a Complex Problem. *Curr Epidemiol Rep*.
633 2018;5(1):1-9.

634 30. Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd. The hidden burden of influenza: A
635 review of the extra-pulmonary complications of influenza infection. *Influenza Other Respir*
636 *Viruses*. 2017 Sep;11(5):372-393.

637 31. GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to
638 influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of
639 Disease Study 2017. *Lancet Respir Med*. 2019 Jan;7(1):69-89.

640 32. Global Consortium for H5N8 and Related Influenza Viruses. Role for migratory wild birds in
641 the global spread of avian influenza H5N8. *Science*. 2016;354(6309):213-217.

642 33. Runstadler J, Hill N, Hussein IT, Puryear W, Keogh M. Connecting the study of wild
643 influenza with the potential for pandemic disease. *Infect Genet Evol.* 2013;17:162-187.

644 34. Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open source tool
645 for metagenomics. *PeerJ.* 2016 Oct 18;4:e2584.

646 35. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL.
647 BLAST+: architecture and applications. *BMC Bioinformatics.* 2009 Dec 15;10:421.

648 36. Zhang Y, Aevermann BD, Anderson TK, Burke DF, Dauphin G, Gu Z, He S, Kumar S,
649 Larsen CN, Lee AJ, Li X, Macken C, Mahaffey C, Pickett BE, Reardon B, Smith T, Stewart
650 L, Suloway C, Sun G, Tong L, Vincent AL, Walters B, Zaremba S, Zhao H, Zhou L, Zmasek
651 C, Klem EB, Scheuermann RH. Influenza Research Database: An integrated bioinformatics
652 resource for influenza virus research. *Nucleic Acids Res.* 2017 Jan 4;45(D1):D466-D474.

653 37. Zhou B, Donnelly ME, Scholes DT, St George K, Hatta M, Kawaoka Y, Wentworth DE.
654 Single-reaction genomic amplification accelerates sequencing and vaccine production for
655 classical and Swine origin human influenza a viruses. *J Virol.* 2009 Oct;83(19):10309-13.

656 38. Spackman E, Senne DA, Myers TJ, et al. Development of a real-time reverse transcriptase
657 PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. *J*
658 *Clin Microbiol.* 2002;40(9):3256-3260. doi:10.1128/JCM.40.9.3256-3260.2002

659 39. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global
660 trends in emerging infectious diseases. *Nature.* 2008 Feb 21;451(7181):990-3.

661 40. Smith KF, Goldberg M, Rosenthal S, Carlson L, Chen J, Chen C, Ramachandran S. Global
662 rise in human infectious disease outbreaks. *J R Soc Interface.* 2014 Dec 6;11(101):20140950.
663 doi: 10.1098/rsif.2014.0950.

664 41. Carroll D, Daszak P, Wolfe ND, Gao GF, Morel CM, Morzaria S, Pablos-Méndez A, Tomori
665 O, Mazet JAK. The Global Virome Project. *Science*. 2018 Feb 23;359(6378):872-874. doi:
666 10.1126/science.aap7463.

667 42. Lipkin WI, Firth C. Viral surveillance and discovery. *Curr Opin Virol*. 2013 Apr;3(2):199-
668 204. doi: 10.1016/j.coviro.2013.03.010. Epub 2013 Apr 17.

669 43. Gardy JL, Loman NJ. Towards a genomics-informed, real-time, global pathogen surveillance
670 system. *Nat Rev Genet*. 2018 Jan;19(1):9-20. doi: 10.1038/nrg.2017.88. Epub 2017 Nov 13.

671 44. Kress WJ, Mazet JAK, Hebert PDN. Opinion: Intercepting pandemics through genomics.
672 *Proc Natl Acad Sci U S A*. 2020 Jun 23;117(25):13852-13855. doi:
673 10.1073/pnas.2009508117. Epub 2020 Jun 3.

674 45. Khoury MJ, Holt KE. The impact of genomics on precision public health: beyond the
675 pandemic. *Genome Med*. 2021;13(1):67. Published 2021 Apr 23. doi:10.1186/s13073-021-
676 00886-y

677 46. Grad YH, Lipsitch M. Epidemiologic data and pathogen genome sequences: a powerful
678 synergy for public health. *Genome Biol*. 2014 Nov 18;15(11):538. doi: 10.1186/s13059-014-
679 0538-4.

680 47. Sintchenko V, Holmes EC. The role of pathogen genomics in assessing disease transmission.
681 *BMJ*. 2015 May 11;350:h1314. doi: 10.1136/bmj.h1314.

682 48. Armstrong GL, MacCannell DR, Taylor J, Carleton HA, Neuhaus EB, Bradbury RS, Posey
683 JE, Gwinn M. Pathogen Genomics in Public Health. *N Engl J Med*. 2019 Dec
684 26;381(26):2569-2580.

685